Biotech entity
Every one of those 1 sits in a single category, pharma. Bill Meury is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Source depth averages 4 original sources per story, versus 2.5 across the same-window beat baseline.
Last mentioned: Aug 1, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. Bill Meury is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Source depth averages 4 original sources per story, versus 2.5 across the same-window beat baseline. Their average consequence score of 6 runs above the beat's 5.7 for that window. DroneDeploy appears in 1 tracked Biotech story from August 1, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 21 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering DroneDeploy. Shared-story counts are live from our verified record — not editorial picks.
Incyte's Q2 net product sales hit $1.49 billion on a 40% jump, powered by Jakafi's 7% growth and a one-time OPZELURA CMS benefit. The biotech raised full-year 2026 revenue guidance to $5.13-5.26 billion and is advancing Jakafi XR with formulary wins, targeting 3-5% demand share by year-end.
Source: Zolmax · Watch List News
DroneDeploy is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
